ImpediMed Limited
IPD
Rank in Stocks
#28689
Operating as a medical software technology provider, ImpediMed Limited is... Operating as a medical software technology provider, ImpediMed Limited is responsible for the development, production, and global sales of bioimpedance spectroscopy (BIS) instruments and accompanying software solutions, serving markets in Australia, North America, and internationally. Its product portfolio features SOZO, a non-invasive BIS device used for evaluating lymphedema and tracking fluid levels in heart failure patients. Additionally, it offers the SFB7, a single-channel, tetrapolar BIS instrument for analyzing body composition in healthy individuals, and ImpediVET, another single-channel, tetrapolar BIS device specifically designed for veterinary applications to measure fluid status and tissue composition. ImpediMed primarily sells its technology to hospitals and clinics. This Australian-headquartered firm, based in Pinkenba, was established in 1999.
Share Price
$0.00276876
Last synced: 2026-11-09
Market Cap
$10.15M
Change (1 day)
33.09%
Change (1 year)
-88.55%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade ImpediMed Limited (IPD)
Category
Healthcare
Operating Margin for ImpediMed Limited (IPD)
Operating Margin as of November 2026 TTM: -117.21%
According to ImpediMed Limited's latest financial reports, its current operating margin (TTM) is -117.21%. At the end of 2025 the company had an operating margin of -190.44%.
Operating Margin history for ImpediMed Limited from 2007 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -117.21% | -38.45% |
| 2025 | -190.44% | 3.23% |
| 2024 | -184.48% | -8.40% |
| 2023 | -201.39% | 0.24% |
| 2022 | -200.90% | -26.60% |
| 2021 | -273.72% | -38.40% |
| 2020 | -444.35% | -31.50% |
| 2019 | -648.70% | -29.92% |
| 2018 | -925.62% | 73.40% |
| 2017 | -533.82% | 8.47% |
| 2016 | -492.13% | 57.41% |
| 2015 | -312.65% | 37.42% |
| 2014 | -227.52% | -34.18% |
| 2013 | -345.66% | -24.40% |
| 2012 | -457.22% | 16.51% |
| 2011 | -392.44% | 22.14% |
| 2010 | -321.30% | -32.14% |
| 2009 | -473.45% | 11.57% |
| 2008 | -424.37% | 0.00% |
| 2007 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 15.24% | -100.13% |
US
|
|
| 18.08% | -100.15% |
IE
|
|
| 21.25% | -100.18% |
US
|
|
| 21.05% | -100.18% |
US
|
|
| 28.09% | -100.24% |
US
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about ImpediMed Limited's operating margin
What is ImpediMed Limited's operating margin?
ImpediMed Limited's operating margin is -117.21%, as of Nov 2026.
What was ImpediMed Limited's operating margin in 2025?
In 2025, ImpediMed Limited's operating margin was -190.44%, compared with -184.48% in 2024.
How has ImpediMed Limited's operating margin changed since 2020?
From 2020 to 2025, ImpediMed Limited's operating margin was highest in 2024 (-184.48%) and lowest in 2020 (-444.35%).
How does ImpediMed Limited's operating margin compare with similar companies?
ImpediMed Limited's operating margin (-117.21%) is lower than that of all 5 similar companies listed above. The highest among them is Edwards Lifesciences Corporation, with 28.09%.